Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323

BACKGROUND: The effectiveness of bevacizumab monotherapy in elderly patients with non-squamous non-small cell lung cancer (NSCLC) is unclear. The efficacy of the combinations for elderly patients was explored. METHODS: Untreated patients (≥75 years; performance status 0–1) with stage IIIB, IV, or re...

Descripción completa

Detalles Bibliográficos
Autores principales: Kozuki, Toshiyuki, Nogami, Naoyuki, Hataji, Osamu, Tsunezuka, Yoshio, Seki, Nobuhiko, Harada, Toshiyuki, Fujimoto, Nobukazu, Bessho, Akihiro, Takamura, Kei, Takahashi, Kazuhisa, Satouchi, Miyako, Kato, Terufumi, Shukuya, Takehito, Yamashita, Natsumi, Okamoto, Hiroaki, Shinkai, Tetsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354128/
https://www.ncbi.nlm.nih.gov/pubmed/32676310
http://dx.doi.org/10.21037/tlcr.2020.03.29

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354128/
https://www.ncbi.nlm.nih.gov/pubmed/32676310
http://dx.doi.org/10.21037/tlcr.2020.03.29

Ejemplares similares